RUMORED BUZZ ON ABBV-744 FOR SMALL CELL LUNG CANCER RESEARCH

In Section C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or the individuals are not able to tolerate the study drugs.Celastrol was discovered as a Myb inhibitor that suppressed C/EBPβ activity and re